<DOC>
	<DOCNO>NCT00652691</DOCNO>
	<brief_summary>RATIONALE : Giving colony-stimulating factor , G-CSF help stem cell move patient 's bone marrow blood collect store . Combination chemotherapy give prepare bone marrow stem cell transplant . The stem cell return patient replace blood-forming cell destroy chemotherapy . PURPOSE : This randomized trial study side effect best dose topotecan give together high-dose cyclophosphamide , carboplatin follow autologous peripheral blood stem cell transplant treat patient recurrent ovarian cancer primary peritoneal cancer .</brief_summary>
	<brief_title>Topotecan , High-Dose Cyclophosphamide , Carboplatin , Autologous Peripheral Blood Cell Transplant Treating Patients With Recurrent Ovarian Cancer Primary Peritoneal Cancer</brief_title>
	<detailed_description>OBJECTIVES : - To determine maximum tolerate dose topotecan hydrochloride combine high-dose cyclophosphamide carboplatin set autologous peripheral blood stem cell transplantation relapse , recurrent , persistent ovarian epithelial primary peritoneal cavity cancer . - To assess toxicity regimen . OUTLINE : This dose escalation study topotecan . - Autologous hematopoietic stem cell collection : Patients receive filgrastim subcutaneously ( SC ) daily 5 day . Patients undergo leukapheresis per standard practice minimum 2 x10^6 CD34+ cells/kg collect cryopreserved . - High-dose chemotherapy : Patients receive topotecan hydrochloride IV , cyclophosphamide IV , carboplatin IV 8 hour day -6 -3 . - Autologous peripheral stem cell reinfusion : Patients undergo autologous peripheral blood stem cell transplantation day 0 . Patients also receive sargramostim SC daily begin day 5 continue blood count recover . After completion study therapy , patient follow monthly 3 month , every 3 month 2 year , every 6 month 5 year .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm ovarian epithelial primary peritoneal cavity cancer Recurrent , relapse , persistent disease meet 1 follow criterion : Patients positive secondlook laparotomy candidate higher priority GOG protocols Largest mass recurrent disease ≤ 0.2 cm achieve surgery chemotherapy Achievement complete response 1 prior regimen platinumbased chemotherapy relapse &gt; 6 month last chemotherapy Achievement partial response 1 platinumbased chemotherapy regimen prior study Histological proof disease recurrence without rise serum CA125 level ( relapsed recurrent disease ) The following histological cell type allow : Clearcell adenocarcinoma Endometrioid adenocarcinoma Mixed epithelial carcinoma Mucinous adenocarcinoma Serous adenocarcinoma Undifferentiated carcinoma Must unilateral bone marrow aspirate biopsy cytogenetics without evidence metastatic ovarian carcinoma conventional morphology within 1 month registration Not eligible GOG164 PATIENT CHARACTERISTICS : ECOG performance status 02 Creatinine ≤ 1.5 mg/dL Total bilirubin ≤ 2.0 mg/dL ( ≤ 5.0 mg/dL metastatic disease ) AST ≤ 2 time upper limit normal ( ULN ) ( ≤ 600 units/mL metastatic disease ) Alkaline phosphatase ≤ 2 time ULN ( unless relate metastatic disease ) ANC ≥ 1,000/mm^3 Platelets ≥ 100,000/mm^3 Cardiac ejection fraction ≥ 45 % rest ECHO MUGA FEV_1 ≥ 50 % predict HIV negative No uncontrolled infection No severe medical psychiatric illness , include follow : Renal failure Brittle insulin dependent diabetes mellitus Congestive heart failure History myocardial infarction within past 3 month Significant arrhythmia require medication Poorly control hypertension ( diastolic blood pressure &gt; 100 mm Hg ) History hospitalization severe depression psychosis Significant nonneoplastic pulmonary disease Current alcohol drug abuse . Active infection Active peptic ulcer disease No prior malignancy within past 5 year except adequately treat basal cell squamous cell carcinoma skin situ cervical carcinoma PRIOR CONCURRENT THERAPY : See Disease Characteristics No 1 prior treatment regimen cancer More 3 week since surgery No prior topotecan hydrochloride</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>peritoneal cavity cancer</keyword>
	<keyword>ovarian clear cell tumor proliferating activity</keyword>
	<keyword>ovarian endometrioid adenocarcinoma</keyword>
	<keyword>ovarian mixed epithelial carcinoma</keyword>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>ovarian mucinous cystadenocarcinoma</keyword>
	<keyword>ovarian serous cystadenocarcinoma</keyword>
	<keyword>ovarian undifferentiated adenocarcinoma</keyword>
</DOC>